Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

Authors: Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A. Ascierto, Jon Richards, Célèste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Cyril Konto, Axel Hoos, Veerle de Pril, Ravichandra Karra Gurunath, Gaetan de Schaetzen, Stefan Suciu, Alessandro Testori - The Lancet 2015 cited by 1,255